<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114324">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01916967</url>
  </required_header>
  <id_info>
    <org_study_id>4117-201</org_study_id>
    <secondary_id>MK-4117-201</secondary_id>
    <nct_id>NCT01916967</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)</brief_title>
  <official_title>A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the efficacy and safety of desloratadine in Japanese
      participants with chronic urticaria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in sum score of pruritus/itch and rash assessed by  investigator at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who experienced at least one adverse event</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who discontinued from study drug due to an adverse event</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sum score of pruritus/itch and rash assessed by investigator</measure>
    <time_frame>Baseline, Day 3, and Week 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pruritus/itch score assessed by investigator</measure>
    <time_frame>Baseline, Day 3, Week 1, and Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in rash score assessed by investigator</measure>
    <time_frame>Baseline, Day 3, Week 1, and Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a moderate or remarkable improvement in the Global Improvement Rate of both pruritus/itch and rash (erythema and wheal) assessed by investigator</measure>
    <time_frame>Baseline, Day 3, Week 1, and Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pruritus/itch score reported in participant's diary</measure>
    <time_frame>Baseline, Day 3, Week 1, and Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in rash score reported in participant's diary</measure>
    <time_frame>Baseline, Day 3, Week 1, and Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Dermatology Life Quality Index (DLQI) score recorded by participants</measure>
    <time_frame>Baseline, Week 1, and Week 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Urticaria</condition>
  <arm_group>
    <arm_group_label>desloratadine (10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>desloratadine 10 mg orally, once daily, two 5-mg tablets in the evening for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>desloratadine (5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>desloratadine, 5 mg orally, once daily, one 5-mg tablet in the evening for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo to desloratadine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desloratadine</intervention_name>
    <description>desloratadine, oral administration in the evening, dosage form is a 5-mg tablet</description>
    <arm_group_label>desloratadine (10 mg)</arm_group_label>
    <arm_group_label>desloratadine (5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo given orally, once daily, as two 5-mg tablets in the evening</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic urticaria [rash (erythema, wheal) for more than 1 month without any known
             cause]

          -  Out-patient

        Exclusion Criteria:

          -  Stimulation-induced urticaria [physical urticaria (e.g. cold, solar, and heat
             urticaria), cholinergic urticaria, contact urticaria)]

          -  Hypersensitivity to antihistamines or ingredients of a study drug
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>August 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urticaria</keyword>
  <keyword>Skin Diseases, Vascular</keyword>
  <keyword>Skin Diseases</keyword>
  <keyword>Hypersensitivity, Immediate</keyword>
  <keyword>Hypersensitivity</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Cholinergic Antagonists</keyword>
  <keyword>Cholinergic Agents</keyword>
  <keyword>Neurotransmitter Agents</keyword>
  <keyword>Histamine H1 Antagonists, Non-Sedating</keyword>
  <keyword>Histamine H1 Antagonists</keyword>
  <keyword>Histamine Antagonists</keyword>
  <keyword>Histamine Agents</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
    <mesh_term>Cholinergic Antagonists</mesh_term>
    <mesh_term>Neurotransmitter Agents</mesh_term>
    <mesh_term>Histamine H1 Antagonists, Non-Sedating</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
